0.3227  -0.014 (-4.02%)		06-09 16:00
Open: 0.3362 High: 0.3448 Volume: 863,638		Pre. Close: 0.3362 Low: 0.32 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	0.4	1-year :	0.46
Resists	First :	0.34	Second :	0.4
Pivot price	0.32
Supports	First :	0.25	Second :	0.2
MAs	MA(5) :	0.34	MA(20) :	0.32
	MA(100) :	0.66	MA(250) :	1.64
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	51.7	D(3) :	62.1
RSI	RSI(14): 46.7
52-week	High :	3.69	Low :	0.25

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MDCX ] has closed above bottom band by 47.6%. Bollinger Bands are 69.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 52 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.35 - 0.35	0.35 - 0.35
Low:	0.32 - 0.32	0.32 - 0.32
Close:	0.32 - 0.32	0.32 - 0.33

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

Mon, 08 Jun 2026
Prostate cancer Teverelix moves toward Phase 2b trial for high-risk patients - Stock Titan

Thu, 04 Jun 2026
Medicus Pharma (MDCX) registers 3.25M shares; warrants exercisable at $4.64 - Stock Titan

Thu, 04 Jun 2026
Medicus Pharma (MDCX) COO awarded 200,000 options at $0.36 exercise price - Stock Titan

Thu, 04 Jun 2026
Director at Medicus Pharma (MDCX) receives grant of 50,000 stock options - Stock Titan

Thu, 04 Jun 2026
Director Patrick Mahaffy receives 50,000 Medicus Pharma (MDCX) stock options at $0.36 - Stock Titan

Thu, 04 Jun 2026
Medicus Pharma (MDCX) director Larry Kaiser awarded 50,000 options at $0.36 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	57 (M)
Held by Insiders	5.014e+007 (%)
Held by Institutions	12.8 (%)
Shares Short	1,270 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-278.2 %
Return on Equity (ttm)	-2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-28 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	2.19e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.